CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, today announced an expansion of roles for the Company’s Executive Vice Presidents aimed at meeting the Company’s evolving business needs and strategic initiatives. Under the new reporting structure, all corporate functions will report to these executives, who will, in turn, continue to report to Gustav Christensen, President and Chief Executive Officer of Dyax. The executives and their responsibilities are:
